By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nuclea Technologies today announced a deal with Boston Medical Center for the discovery of new gene expression biomarkers to diagnose cancer.

Under the partnership, research will be directed at gene expression in specific tumors to help radiologists "review results in a different and more comprehensive way," Nuclea said in a statement.

Based in Pittsfield, Mass., Nuclea discovers and develops genetic, protein, and antibody biomarkers and diagnostic assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.